Prateek Bedi, Nityashjit Kaur 
Dealstreet

Dua Associates advises SWAMIH Investment Fund-I on ₹399.5 crore Last-Mile Financing for Greater Noida Residential Project

The transaction aligns with SWAMIH Investment Fund-I’s mission of delivering approximately 20,000 homes annually.

Bar & Bench

SBI Ventures Limited’s SWAMIH Investment Fund-I has provided ₹399.5 crore as financing to SRK Buildwell Private Limited for the residential development Project Morpheus Pratiksha—soon to be rebranded as Project Nirala Grand—located in Sector 1, Greater Noida, Uttar Pradesh.

Dua Associates advised and assisted SWAMIH Investment Fund-I on this transaction. The Firm advised across the full lifecycle of the transaction, including legal due diligence, transaction structuring, documentation, and ongoing legal support through execution and closing.

The Corporate Due Diligence and Documentation team was led by Prateek Bedi (Partner) and Nityashjit Kaur (Partner), with Rishabh Halwai (Senior Associate), Vaibhav Tripathi (Senior Associate) and Anukriti Prakash (Associate).

The Title Verification team was led by Angad Verma (Partner) and supported by Toyesh Tewari (Partner) and Kapil Saxena (Principal Associate).

The transaction, completed in late November 2025, aligns with SWAMIH Investment Fund-I’s mission of delivering approximately 20,000 homes annually, reinforcing its role in restoring buyer confidence and accelerating housing completion across India.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.

Litigant attempts to throw purse at Bombay High Court judge; Court initiates contempt case

Supreme Court asks Law Commission to propose reforms for speedy execution of arbitral awards

Plea before Supreme Court against exclusion of charitable, sovereign activities from definition of 'industry' under IR Code

Morrison Foerster, Khaitan & Co advises Autodesk on acquisition of select tech assets, intellectual property from BIMDeX

Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers

SCROLL FOR NEXT